SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (2393)2/18/1998 4:23:00 PM
From: Linda Kaplan  Read Replies (3) of 7041
 
Dauntless,

There were two paragraphs on Zonagen. One on page one and one on page two, but the second paragraph reiterated the first paragraph and expanded the details. I posted all the relevant details about Zonagen that were in the report. But perhaps there is supplementary information that you can dig up?

I think there has to be high, low and medium doses of Vasomax. Wessels, Arnold & Henderson is supposed to have a good rep and it would not provide any advantage to them to create a report of this kind that isn't accurate, for they are accountable to their clients, after all and the investment community as a whole.

Isn't the conference being held by the very people (Wessels, Arnold & Henderson) who prepared this report?

Yes, you're right. The report discusses VVUS, recommending a "Hold" on VVUS, and I didn't mention that. But there wasn't anything else about Zonagen.

Linda
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News